Trexquant Investment LP purchased a new position in shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 42,535 shares of the biopharmaceutical company’s stock, valued at approximately $321,000. Trexquant Investment LP owned about 0.07% of Corbus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Corbus Pharmaceuticals by 52.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 35,884 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 12,380 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Corbus Pharmaceuticals by 2,742.5% during the 1st quarter. Royal Bank of Canada now owns 51,961 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 50,133 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Corbus Pharmaceuticals by 61.5% during the 3rd quarter. Alliancebernstein L.P. now owns 55,400 shares of the biopharmaceutical company’s stock worth $418,000 after acquiring an additional 21,100 shares during the last quarter. Alps Advisors Inc. bought a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter worth approximately $419,000. Finally, Woodstock Corp lifted its stake in shares of Corbus Pharmaceuticals by 29.5% during the 3rd quarter. Woodstock Corp now owns 93,264 shares of the biopharmaceutical company’s stock worth $704,000 after acquiring an additional 21,263 shares during the last quarter. 43.87% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ CRBP opened at $6.90 on Friday. The firm has a market cap of $381.20 million, a price-to-earnings ratio of -10.62 and a beta of 2.15. Corbus Pharmaceuticals Holdings Inc has a twelve month low of $4.50 and a twelve month high of $9.95.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.05). The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $1.66 million. On average, equities research analysts predict that Corbus Pharmaceuticals Holdings Inc will post -0.86 earnings per share for the current year.

A number of brokerages recently issued reports on CRBP. Royal Bank of Canada began coverage on Corbus Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $23.00 price target for the company. ValuEngine lowered Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 15th. BidaskClub lowered Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. Cantor Fitzgerald reissued a “buy” rating and set a $36.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, October 22nd. Finally, B. Riley began coverage on Corbus Pharmaceuticals in a research note on Wednesday, October 24th. They set a “buy” rating and a $22.00 price target for the company. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Corbus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $26.25.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2018/12/08/trexquant-investment-lp-purchases-new-position-in-corbus-pharmaceuticals-holdings-inc-crbp.html.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

Recommended Story: Dividend Aristocrat Index

Institutional Ownership by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.